ASRM 2019 — Aneuploidy: preimplantation genetic testing improves perinatal outcomes


  • Daniel M. Keller, Ph.D
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preimplantation genetic testing and frozen embryo transfer (PGT-FET) has several benefits on perinatal outcomes of the newborn, including lower risk of low birth weight (LBW) and preterm delivery.
  • No harms resulted from biopsy of the embryo.

Why this matters

  • Studies have shown differences in LBW and preterm delivery following in vitro fertilization vs natural conception.
  • PGT and FET are increasingly common, but perinatal outcomes have not been studied.

Study design  

  • Retrospective cohort study using Society for Assisted Reproductive Technology database.
  • Compared day-5 autologous FET cycles undergoing PGT (n=10,367) vs no PGT (n=39,570).
  • Financial support: None.

Key results

  • PGT group mean age: 35.6 vs 33.9 years no PGT (P<.01>
  • Mean number of embryos transferred: PGT 1.2 vs no PGT 1.6 (P<.01>
  • Primary outcome — LBW rate: PGT 16.5% vs no PGT 23.8% (adjusted risk ratio [aRR], 0.74; 95% CI, 0.66-0.83).
  • Clinical pregnancy rate: PGT 64.9% vs no PGT 57.7% (aRR, 1.16; 95% CI, 1.13-1.19).
  • Live birth rate: PGT 56.2% vs no PGT 46.8% (aRR, 1.25; 95% CI, 1.21-1.30).
  • Multiple gestation rate: PGT 12.6% vs no PGT 21.4% (aRR, 0.68; 95% CI, 0.60-0.77).

Limitations

  • Could not determine day of biopsy from data set.
  • Information could be missing from data set.